SPY334.57+0.24 0.07%
DIA274.62+0.72 0.26%
IXIC11,010.98-97.09 -0.87%

Baird Downgrades Cellular Biomedicine Gr to Neutral, Lowers Price Target to $19

Baird downgrades Cellular Biomedicine Gr (NASDAQ:CBMG) from Outperform to Neutral and lowers the price target from $26 to $19.

Benzinga · -

Baird downgrades Cellular Biomedicine Gr (NASDAQ:CBMG) from Outperform to Neutral and lowers the price target from $26 to $19.